Get started
Live feed
·
PRReleasevia Quantisnow
ArriVent BioPharma Inc. logo

ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026

ByQuantisnow·Wall Street's wire, on your screen.
AVBPArriVent BioPharma Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AVBP (ArriVent BioPharma Inc.) and more on Quantisnow.